Table 1.
Patient demographics
| Total | N = 25 |
|---|---|
| Age, years | 65 ± 12 |
| Male | 18 (72%) |
| Median duration of AF, months | 10 (IQR: 6‐12) |
| BMI, kg/m2 | 28 ± 4 |
| Comorbidities | |
| Hypertension | 10 (40%) |
| Diabetes mellitus | 5 (20%) |
| Heart failure, NYHA ≥ 2 | 9 (36%) |
| Antiarrhythmic medications | |
| Beta‐blockers | 23 (92%) |
| Flecainide | 4 (16%) |
| Amiodarone | 3 (12%) |
| Anticoagulation | |
| Warfarin | 4 (16%) |
| Apixaban | 10 (40%) |
| Dabigatran | 5 (20%) |
| Rivaroxaban | 6 (24%) |
| Previous failed DCCV | 22 (88%) |
| LA diameter, mm | 44 ± 6 |
| LVEF, % | 55 (IQR: 35‐60) |
| CHA2DS2‐VASc > 2 | 16 (64%) |
Values are mean ± SD, n (%), or median (interquartile range, IQR).
Abbreviations: AF, atrial fibrillation; BMI, body mass index; DCCV, direct current cardioversion; LA, left atrial; LVEF, left ventricular ejection fraction.